CASE STUDIES
Every project
is unique
Recon is not a place to bring your cookie-cutter assignments. We like to work on difficult strategy questions and each of our projects is bespoke. That said, we have the domain knowledge and process expertise that comes from having worked on hundreds of projects across all healthcare sectors.
Here is a sample of "sanitized" case examples.
- Institutional
Strategy for Statewide Health Information Exchange
A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable
HIE, Health IT,
- Medtech, Early Stage
Growth strategy for point-of-care testing
Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform
Growth, product market fit, value proposition
- Institutional
University Trials
Large university wanting to dramatically increase its clinical research footprint
- Providers, Digital health
Direct-to-employer care growth strategy
A direct-to-employer primary care provider had outgrown word-of-mouth selling and its leadership and board disagreed on where the next phase of growth should come from.
Employer segmentation and targeting
- Medtech, Early Stage
Device market entry strategy
An early-stage technology could digitize a large analog device market but needed the board aligned on which market to enter first, and on what terms to engage incumbents, before its Series A ran out.
Digital diagnostic business case
- Biopharma, Early Stage
Biologics formulation platform diligence
A private equity investor weighing a bet on a novel delivery platform needed to know whether scientific novelty would convert into commercial value.
Subcutaneous biologics platform investment
- Biopharma, Digital health
Decentralized clinical trial product strategy
A large pharma health-tech arm needed to understand why its decentralized-trial tools weren't landing with users and how to find a defensible point of differentiation.
Clinical research product roadmap
- Payers, Digital health
Genomics portfolio expansion
A genomics company believed customers would buy a broader population health offering, but needed the use cases proven and leadership convinced before committing.
New service line validation
- Medtech, Early Stage
Molecular diagnostics growth strategy
A molecular diagnostics developer had more new-test opportunities than it could fund and no shared view of which it was equipped to win or whether the economics could work.
New test portfolio prioritization
- Biopharma, Early Stage
Gene therapy disease assessment
A gene therapy biotech with a novel approach to a fast-moving disease area needed an objective read on the opportunity and on whether it had a credible path to win there.
Crowded market entry decision